Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

190.85 -0.05 (-0.03%)
Official Closing Price Updated: 7:00 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
AI Revolutionizes Quality Control: A New Era of Precision and Speed in Manufacturing, Electronics, and Pharmaceuticals
A groundbreaking wave of Artificial Intelligence (AI) tools is poised to fundamentally transform materials quality checking, ushering in an era of unparalleled precision, speed, and cost-efficiency... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
Looking At Johnson & Johnson's Recent Unusual Options Activity
 
Via Benzinga
The Gathering Storm: AI Overbuilding, Trade Wars, and National Debt Fuel Market Crash Fears
As of October 14, 2025, a palpable sense of unease permeates global financial markets, with a growing chorus of analysts and institutions warning of a potential market crash. The prevailing sentiment... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Johnson & Johnson To Separate Its Orthopedic Business
Via Stocktwits
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In
Via Stocktwits
Johnson & Johnson To Spin Off Orthopedics Unit After Raising 2025 Sales Forecast
Johnson & Johnson on Tuesday lifted its 2025 revenue guidance after posting stronger-than-expected third-quarter earnings. 
Via Talk Markets
S&P Drug Titan J&J Dips After Announcing A Surprise Spinoff
The news comes alongside a third-quarter beat and sales guidance hike. 
Via Investor's Business Daily
Topics Stocks
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook
Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes. 
Via Benzinga
Johnson & Johnson (NYSE:JNJ) Beats Q3 2025 Estimates and Raises Full-Year Sales Outlook
Johnson & Johnson (JNJ) beat Q3 2025 earnings estimates, raised its full-year sales outlook, and announced a planned spin-off of its Orthopedics business. 
Via Chartmill
Stock Market Today: S&P 500, Nasdaq Futures Tumble Ahead Of Big Bank Earnings—Goldman Sachs, JPMorgan, Citigroup In Focus
U.S. stock futures declined on Tuesday following Monday’s reversal rally. Futures of major benchmark indices were lower. 
Via Benzinga
Topics Stocks
Why Did Protagonist Therapeutics Stock Soar Today?
Via Stocktwits
Earnings Scheduled For October 14, 2025
 
Via Benzinga
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline. 
Via Stocktwits
Topics Government World Trade
Goldman Sachs, JPMorgan Chase And 3 Stocks To Watch Heading Into Tuesday
US stock futures lower, focus on Goldman Sachs, JPMorgan, Polaris, Johnson & Johnson, and Citigroup earnings. 
Via Benzinga
Big Money Move: Investment Manager Buys $6.9 Million Worth of Johnson & Johnson Shares, According to Recent Filing
Via The Motley Fool
Topics Regulatory Compliance
Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside
Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion sales by 2035. 
Via Benzinga
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst. 
Via Benzinga
Dividend Powerhouses: Should You Grab These 3 Before Earnings Drop?
As the Q3 2025 earnings season hits full stride, a critical question looms for income-focused investors: are "dividend powerhouses" still a safe haven, and should they be considered before their... 
Via MarketMinute
Topics Bonds Earnings Economy
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy
FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit. 
Via Benzinga
Dow Jones Soars on Trump's Tariff Remarks, Signaling Market Volatility Amidst Trade Policy Shifts
New York, NY – October 13, 2025 – The Dow Jones Industrial Average has experienced significant upward momentum in recent months, notably jumping by hundreds of points on multiple occasions in early... 
Via MarketMinute
Topics Economy Government Stocks
A Peek at Johnson & Johnson's Future Earnings
 
Via Benzinga
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
Now may be the time to invest in drug companies, as they just slipped the tariff noose. 
Via The Motley Fool
Topics ETFs Government World Trade
Retail Investors' Top Stocks With Earnings This Week: Fastenal, ASML, TSMC And More
Retail investors are preparing for the kick-off of the Q3 earnings season, with big banks and other top stocks reporting this week. 
Via Benzinga
Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears
U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and... 
Via Chartmill
Topics Artificial Intelligence Government World Trade
Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal
Via The Motley Fool
Topics Regulatory Compliance
US Government Shutdown Rattles Global Markets, Igniting Uncertainty and Fueling Losses on October 10, 2025
The ongoing U.S. federal government shutdown, now in its tenth day as of October 10, 2025, has sent significant tremors through global financial markets. The persistent congressional deadlock over... 
Via MarketMinute
Topics Bonds Economy World Trade
Market Turmoil: S&P 500 and Nasdaq Plunge Amidst Renewed Trade Tensions and AI Scrutiny
New York, NY – October 10, 2025 – U.S. equity markets experienced a dramatic downturn today, with both the S&P 500 and Nasdaq Composite indices recording substantial losses, shattering a months-long... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio. 
Via Benzinga
Is This Beaten-Down Dividend King a Buy?
This company's short life on the stock market has been a constant challenge. 
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.